Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial

被引:248
作者
Aslanyan, S [1 ]
Weir, CJ
Diener, HC
Kaste, M
Lees, KR
机构
[1] Univ Glasgow, Western Infirm, Gardiner Inst, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Essen Gesamthsch, Dept Neurol, Essen, Germany
[4] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland
关键词
ischaemic stroke; pneumonia; urinary tract infection;
D O I
10.1046/j.1468-1331.2003.00749.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The third most common stroke complication is infection. We studied the rates of aspiration pneumonia and urinary tract infection (UTI), their risk factors and their effect on outcome in the 1455 Glycine Antagonist (Gavestinel) in Neuroprotection (GAIN) International patients with ischaemic stroke. Forward stepwise logistic regression and Cox proportional hazards modelling identified baseline factors that predicted events and the independent effect of events up to day 7 on poor stroke outcome at 3 months in patients alive at day 7, after correcting for prognostic factors. Higher baseline National Institute of Health Stroke Scale (NIHSS) and age, male gender, history of diabetes and stroke subtype predicted pneumonia, which occurred in 13.6% of patients. Female gender and higher baseline NIHSS and age predicted UTI, which occurred in 17.2% of patients. Pneumonia was associated with poor outcome by mortality (hazard ratio, 2.2; 95% confidence interval, 1.5-3.3), Barthel index (<60) (odds ratio, 3.8; 2.2-6.7), NIHSS (4.9; 1.7-14) and Rankin scale (greater than or equal to2) (3.4; 1.4-8.3). UTI was associated with Barthel index (1.9; 1.2-2.9), NIHSS (2.2; 1.2-4.0) and Rankin scale (3.1; 1.6-4.9). Pneumonia and UTI are independently associated with stroke poor outcome. Patients with identified risk factors must be closely monitored for infection.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 13 条
  • [1] CLASSIFICATION AND NATURAL-HISTORY OF CLINICALLY IDENTIFIABLE SUBTYPES OF CEREBRAL INFARCTION
    BAMFORD, J
    SANDERCOCK, P
    DENNIS, M
    BURN, J
    WARLOW, C
    [J]. LANCET, 1991, 337 (8756) : 1521 - 1526
  • [2] Complications after acute stroke
    Davenport, RJ
    Dennis, MS
    Wellwood, I
    Warlow, CP
    [J]. STROKE, 1996, 27 (03) : 415 - 420
  • [3] The role of inflammation after acute stroke - Utility of pursuing anti-adhesion molecule therapy
    DeGraba, TJ
    [J]. NEUROLOGY, 1998, 51 (03) : S62 - S68
  • [4] Cerebral ischemia and inflammation
    Iadecola, C
    Alexander, M
    [J]. CURRENT OPINION IN NEUROLOGY, 2001, 14 (01) : 89 - 94
  • [5] Iadecola C, 1997, J NEUROSCI, V17, P9157
  • [6] Medical and neurological complications of ischemic stroke - Experience from the RANTTAS trial
    Johnston, KC
    Li, JY
    Lyden, PD
    Hanson, SK
    Feasby, TE
    Adams, RJ
    Faught, RE
    Haley, EC
    [J]. STROKE, 1998, 29 (02) : 447 - 453
  • [7] Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
    Lees, KR
    Asplund, K
    Carolei, A
    Davis, SM
    Diener, HC
    Kaste, M
    Orgogozo, JM
    Whitehead, J
    [J]. LANCET, 2000, 355 (9219) : 1949 - 1954
  • [8] The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene
    Nagayama, M
    Niwa, K
    Nagayama, T
    Ross, ME
    Iadecola, C
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1999, 19 (11) : 1213 - 1219
  • [9] Nogawa S, 1997, J NEUROSCI, V17, P2746
  • [10] Sherman DG, 1997, NEUROLOGY, V48, P33001